What are the indications approved by the FDA for ipilimumab?

Ipilimumab is a first-order human monoclonal antibody against CTLA-4.
It inhibits CD80 and CD86 on antigen-presenting cell forms, binding to CTLA-4 on T lymphocytes.
Blocking the CTLA-4 signaling prolongs the activation and proliferation of T lymphocytes, and amplifies immunity.
a. Melanoma maligno irresecable o metastásico.
b. Sarcoma de Kaposi relacionado con el SIDA.
c. Hepatitis C crónica.
d. Verrugas genitales y perianales causadas por el virus del papiloma humano (VPH).